ArQule to Report First Quarter 2014 Financial Results on May 7, 2014
WOBURN, Mass. -- April 30, 2014
ArQule, Inc. (NASDAQ: ARQL) today announced that it will report its financial
results for the first quarter of 2014 on Wednesday, May 7, 2014 at 7:00 a.m.
Eastern Time. The Company will hold a conference call at 9:00 a.m. Eastern
Time that day to discuss these results.
Conference Call and Webcast
Date: Wednesday, May 7, 2014
Time: 9:00 a.m., Eastern Time
Conference Call Numbers
Domestic (toll free): (877) 868-1831
International: (914) 495-8595
A replay of the conference call will be available beginning two hours after
the completion of the call until the end of May 9, 2014 and can be accessed by
dialing toll-free 855-859-2056 or 800-585-8367, and outside the U.S.
404-537-3406. The confirmation code for replayed calls is 30148648.
ArQule is a biotechnology company engaged in the research and development of
next-generation, small-molecule cancer therapeutics. The Company’s targeted,
broad-spectrum products and research programs are focused on key biological
processes that are central to human cancers. ArQule’s lead product, in Phase 2
and Phase 3 clinical development, is tivantinib (ARQ 197), an oral, selective
inhibitor of the c-MET receptor tyrosine kinase. The Company’s pipeline
includes ARQ 092, designed to inhibit the AKT serine/threonine kinase, and ARQ
087, designed to inhibit fibroblast growth factor receptor (FGFR). ArQule’s
current discovery efforts, which are based on the ArQule Kinase Inhibitor
Platform (AKIP™), are focused on the identification of novel kinase inhibitors
that are potent, selective and do not compete with ATP (adenosine
triphosphate) for binding to the kinase.
William B. Boni, 781-994-0300
VP, Investor Relations/
Press spacebar to pause and continue. Press esc to stop.